News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

|Videos|May 15, 2023

Approaches to Target Sebum Production

Author(s)Christopher G. Bunick, MD, PhD

Dr Christopher Bunick discusses the role the microbiome and sebum play in acne production and highlights the role Clascoterone cream 1% plays in targeting these agents.

Episodes in this series

EP. 1 Expert Perspectives on a Recent Approval in Acne Management

EP. 1 Expert Perspectives on a Recent Approval in Acne Management

EP. 2 Treatment Selection Considerations for Mild to Moderate Acne

EP. 2 Treatment Selection Considerations for Mild to Moderate Acne

EP. 3 Unmet Needs and the Role of Consensus Guidelines in Acne Management

EP. 3 Unmet Needs and the Role of Consensus Guidelines in Acne Management

EP. 4 Future Directions and Practice Pearls for the Management of Acne

EP. 4 Future Directions and Practice Pearls for the Management of Acne

EP. 5 Expert Perspective on Tailoring Acne Treatments

EP. 5 Expert Perspective on Tailoring Acne Treatments

EP. 6 Skin Care Regimens for Acne Treatment

EP. 6 Skin Care Regimens for Acne Treatment

EP. 7 Acne Treatment Selection Considerations

EP. 7 Acne Treatment Selection Considerations

EP. 8 Overview of Isotretinoin Use and Indication in Acne Management

EP. 8 Overview of Isotretinoin Use and Indication in Acne Management

EP. 9 Expert Perspective on Available Isotretinoin Formulations

EP. 9 Expert Perspective on Available Isotretinoin Formulations

EP. 10 Expert Recommendations for Setting and Managing Acne Treatment Goals with Patients

EP. 10 Expert Recommendations for Setting and Managing Acne Treatment Goals with Patients

EP. 11 Overview of Acne Causes and Triggers

EP. 11 Overview of Acne Causes and Triggers

EP. 12 Considerations for Generic vs Brand Acne Treatment Formulations

EP. 13 Expert Perspectives on Acne Causes and Triggers

EP. 13 Expert Perspectives on Acne Causes and Triggers

EP. 14 Overview of Isotretinoin MOA and Utilization

EP. 14 Overview of Isotretinoin MOA and Utilization

EP. 15 Frontline Forum Part 1: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 15 Frontline Forum Part 1: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 16 Frontline Forum Part 2: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 16 Frontline Forum Part 2: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 17 Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 17 Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 18 Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 18 Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

EP. 19 Expert Perspective on the Management of Acne

EP. 19 Expert Perspective on the Management of Acne

EP. 20 Treatment Selection in Patients with Acne Vulgaris

EP. 20 Treatment Selection in Patients with Acne Vulgaris

EP. 21 Differences in Isotretinoin Formulation

EP. 21 Differences in Isotretinoin Formulation

EP. 22 Expert Perspective on the Utilization of Clascoterone Cream 1%

EP. 22 Expert Perspective on the Utilization of Clascoterone Cream 1%

EP. 23 Utilization of Isotretinoin in Patients with Severe Acne

EP. 23 Utilization of Isotretinoin in Patients with Severe Acne

EP. 24 Expert Insights into the Safety of Isotretinoin

EP. 24 Expert Insights into the Safety of Isotretinoin

EP. 25 Overview and Prevalence of Acne Vulgaris

EP. 25 Overview and Prevalence of Acne Vulgaris

EP. 26 Approaches to Target Sebum Production

EP. 26 Approaches to Target Sebum Production

EP. 27 Expert Insights into the Use of Isotretinoin

EP. 27 Expert Insights into the Use of Isotretinoin

EP. 28 Advances in Acne Management

EP. 28 Advances in Acne Management

EP. 29 Expert Opinion on the Utility of Guidelines in Patient Care

EP. 29 Expert Opinion on the Utility of Guidelines in Patient Care

EP. 30 Novel Approach to Sebum Production

EP. 30 Novel Approach to Sebum Production

EP. 31 Expert Insights into the Importance of Active Components in Acne Treatments

EP. 31 Expert Insights into the Importance of Active Components in Acne Treatments

EP. 32 Frontline Forum Part 1: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 32 Frontline Forum Part 1: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 33 Frontline Forum Part 2: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 33 Frontline Forum Part 2: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 34 Frontline Forum Part 3: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 34 Frontline Forum Part 3: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 35 Frontline Forum Part 4: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 35 Frontline Forum Part 4: A Greater Understanding of the Acne Vulgaris Armamentarium

EP. 36 Discovering Dermatology Times: August 2023 Acne Vulgaris Supplement

EP. 36 Discovering Dermatology Times: August 2023 Acne Vulgaris Supplement

EP. 37 Top 5 Clinical Pearls for Acne Vulgaris Management

EP. 37 Top 5 Clinical Pearls for Acne Vulgaris Management

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Syrian Study Confirms Isotretinoin’s Effectiveness in Acne Treatment

ByMaddi Hebebrand, MC, Associate Editor

December 2nd 2025

Q&A: Dermatologists' Critical Role in Managing Cutaneous Toxicities in Lung Cancer Therapy

ByMarie Bosslett, Assistant Editor,Mondana Ghias, MD, FAAD

December 2nd 2025

Clinical Guidance Needed as Patients Turn to Tallow for Skin Conditions

ByMaddi Hebebrand, MC, Associate Editor

December 1st 2025

Elevate-Derm Takeaways: Acne Innovation, Alopecia Care, and Cross-Specialty Insights

ByJames Canner, PA-C,Kaitlyn Bader, Assistant Managing Editor

November 25th 2025

Journal Digest: November 19, 2025

ByMarie Bosslett, Assistant Editor

November 19th 2025

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population

Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema

When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria

Top 5 Articles of the Week: December 7-12

Dermatology Times Spot Test: December 14, 2025

© 2025 MJH Life Sciences^®

All rights reserved.